2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.10 Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases

P2.11A.10 Impact of Baseline Glucocorticoid Use on the Efficacy of Immunoradiotherapy in NSCLC Patients with Brain Metastases

Back to course

Pdf Summary

The study examines the impact of baseline glucocorticoid (GCs) use on the efficacy of immunotherapy combined with intracranial radiotherapy in patients with non-small cell lung cancer (NSCLC) and brain metastases. GCs, often administered to manage cerebral edema, might reduce the effectiveness of such combination therapies due to their negative impact on immunotherapy.<br /><br />The researchers analyzed data from 62 NSCLC patients, categorizing them based on their baseline GCs usage into three groups: low (30 mg), medium (30-100 mg), and high (100 mg). The study aimed to understand how these GCs doses affected intracranial progression-free survival (iPFS), progression-free survival (PFS), and overall survival (OS).<br /><br />Results indicated that increased baseline use of GCs is linked to a reduced efficacy of the combination therapy, with high-dose GCs (100 mg) notably impairing survival outcomes. The study found that high baseline GCs doses negatively affected iPFS, PFS, and OS compared to lower doses. Cox proportional hazard models and propensity score matching (PSM) were employed to ensure the balance of variables and accurate assessment of survival outcomes.<br /><br />The study underscores the importance of considering the dose of glucocorticoids used in NSCLC patients with brain metastases undergoing immunotherapy and radiotherapy, advising cautious use of GCs to preserve the benefits of these treatments. This research contributes to better-informed clinical decisions regarding GC use to optimize therapeutic outcomes for affected patients.<br /><br />Funding for the study was provided by the CQMU Program for Youth Innovation in Future Medicine, the Kuanren Talents Program, and the China Postdoctoral Science Foundation.

Asset Subtitle

Yuan Peng

Meta Tag

Speaker Yuan Peng

Topic Metastatic NSCLC – Immunotherapy

Keywords

glucocorticoid

immunotherapy

intracranial radiotherapy

non-small cell lung cancer

brain metastases

baseline GCs

survival outcomes

Cox proportional hazard models

propensity score matching

clinical decisions